Skip to main content


Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

Fig. 3

Proportion of patients who achieved a clinical remission, defined as DAS28-CRP <2.6, b functional remission, defined as HAQ-DI ≤0.5, at weeks 52, 104, 156, and 208, and c structural remission, defined as ΔmTSS ≤0.5 per year, within specified 52-week periods. ADA Adalimumab, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, mTSS Modified total Sharp score, ΔmTSS Change in modified total Sharp score

Back to article page